^
    Back
    Association details:
    Biomarker:MTOR mutation
    Cancer:Renal Cell Carcinoma
    Drug:everolimus (mTOR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma

    Excerpt:
    ...Best Overall Response Rate`Best Overall Response by PI3K-AKT-MTOR Mutation...
    Trial ID:
    NCT00827359
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic Renal Cell Carcinoma

    Excerpt:
    Mutations in MTOR, TSC1 or TSC2 were more common in responders, 12 (28%) of 43, than non-responders, 4 (11%) of 36 (p=0.06). Mutations in TSC1 or TSC2 alone were also more common in responders, 9 (21%), than non-responders, 2(6%), (p=0.05). Furthermore, 5 (42%) of 12 subjects with PR had mutations in MTOR, TSC1 or TSC2 compared to 4 (11%) of 36 non-responders (p=0.03)...Thirty-eight (48%) were treated with everolimus and 41 (52%) received temsirolimus.
    DOI:
    10.1158/1078-0432.CCR-15-2631